Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
Context: Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD). Aims: To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AM...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2011-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2011;volume=59;issue=3;spage=191;epage=196;aulast=Biswas |
| _version_ | 1828542189666304000 |
|---|---|
| author | Partha Biswas Subhrangshu Sengupta Ruby Choudhary Subhankar Home Ajoy Paul Sourav Sinha |
| author_facet | Partha Biswas Subhrangshu Sengupta Ruby Choudhary Subhankar Home Ajoy Paul Sourav Sinha |
| author_sort | Partha Biswas |
| collection | DOAJ |
| description | Context: Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD). Aims: To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD. Settings and Design: Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India. Materials and Methods: One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant. Results: The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed. Conclusions: Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD. |
| first_indexed | 2024-12-12T01:51:45Z |
| format | Article |
| id | doaj.art-c1a0c0dbda7d4d6ba0c5d0c9f43d43a5 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-12-12T01:51:45Z |
| publishDate | 2011-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-c1a0c0dbda7d4d6ba0c5d0c9f43d43a52022-12-22T00:42:27ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892011-01-0159319119610.4103/0301-4738.81023Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degenerationPartha BiswasSubhrangshu SenguptaRuby ChoudharySubhankar HomeAjoy PaulSourav SinhaContext: Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD). Aims: To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD. Settings and Design: Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India. Materials and Methods: One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant. Results: The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed. Conclusions: Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD.http://www.ijo.in/article.asp?issn=0301-4738;year=2011;volume=59;issue=3;spage=191;epage=196;aulast=BiswasAhmed glaucoma valvehypotonypost-penetrating-keratoplasty glaucomatube extrusionscleral patchRanibizumabbevacizumabchoroidal neovascular membraneage-related macular degenerationintravitreal injectioncentral macular thicknessbest corrected visual acuity |
| spellingShingle | Partha Biswas Subhrangshu Sengupta Ruby Choudhary Subhankar Home Ajoy Paul Sourav Sinha Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Indian Journal of Ophthalmology Ahmed glaucoma valve hypotony post-penetrating-keratoplasty glaucoma tube extrusion scleral patch Ranibizumab bevacizumab choroidal neovascular membrane age-related macular degeneration intravitreal injection central macular thickness best corrected visual acuity |
| title | Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration |
| title_full | Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration |
| title_fullStr | Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration |
| title_full_unstemmed | Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration |
| title_short | Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration |
| title_sort | comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age related macular degeneration |
| topic | Ahmed glaucoma valve hypotony post-penetrating-keratoplasty glaucoma tube extrusion scleral patch Ranibizumab bevacizumab choroidal neovascular membrane age-related macular degeneration intravitreal injection central macular thickness best corrected visual acuity |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2011;volume=59;issue=3;spage=191;epage=196;aulast=Biswas |
| work_keys_str_mv | AT parthabiswas comparativeroleofintravitrealranibizumabversusbevacizumabinchoroidalneovascularmembraneinagerelatedmaculardegeneration AT subhrangshusengupta comparativeroleofintravitrealranibizumabversusbevacizumabinchoroidalneovascularmembraneinagerelatedmaculardegeneration AT rubychoudhary comparativeroleofintravitrealranibizumabversusbevacizumabinchoroidalneovascularmembraneinagerelatedmaculardegeneration AT subhankarhome comparativeroleofintravitrealranibizumabversusbevacizumabinchoroidalneovascularmembraneinagerelatedmaculardegeneration AT ajoypaul comparativeroleofintravitrealranibizumabversusbevacizumabinchoroidalneovascularmembraneinagerelatedmaculardegeneration AT souravsinha comparativeroleofintravitrealranibizumabversusbevacizumabinchoroidalneovascularmembraneinagerelatedmaculardegeneration |